Skip Nav Destination
Issues
1 May 2002
ISSN 1078-0432
EISSN 1557-3265
Report from the FDA
Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia
Martin H. Cohen; Grant Williams; John R. Johnson; John Duan; Jogarao Gobburu; Atiqur Rahman; Kimberly Benson; John Leighton; Sung K. Kim; Rebecca Wood; Mark Rothmann; Gang Chen; Khin Maung U; Ann M. Staten; Richard Pazdur
The Cooperative Group Bulletin Board
Review
The Biology Behind
Advances in Brief
T-Cell Responses against Tyrosinase 368–376(370D) Peptide in HLA∗A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants1
Susanne G. Schaed; Virginia M. Klimek; Katherine S. Panageas; Cristina M. Musselli; Leah Butterworth; Wen-Jen Hwu; Philip O. Livingston; Linda Williams; Jonathan J. Lewis; Alan N. Houghton; Paul B. Chapman
p53 Mutations in Leukemia and Myelodysplastic Syndrome after Ovarian Cancer1
Debra G. B. Leonard; Lois B. Travis; Kathakali Addya; Graca M. Dores; Eric J. Holowaty; Kjell Bergfeldt; David Malkin; Betsy A. Kohler; Charles F. Lynch; Tom Wiklund; Marilyn Stovall; Per Hall; Eero Pukkala; Diana J. Slater; Carolyn A. Felix
17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts1
David B. Solit; Fuzhong F. Zheng; Maria Drobnjak; Pamela N. Münster; Brian Higgins; David Verbel; Glenn Heller; William Tong; Carlos Cordon-Cardo; David B. Agus; Howard I. Scher; Neal Rosen
Regular Articles
Clinical Trials
Induction of p53-specific Immune Responses in Colorectal Cancer Patients Receiving a Recombinant ALVAC-p53 Candidate Vaccine1
Sjoerd H. van der Burg; Anand G Menon; Anke Redeker; Marie-Claude Bonnet; Jan Wouter Drijfhout; Rob A. E. M. Tollenaar; Cornelis J. H. van de Velde; Philippe Moingeon; Peter J. K. Kuppen; Rienk Offringa; Cornelis J. M. Melief
Encapsulated Plasmid DNA Treatment for Human Papillomavirus 16-associated Anal Dysplasia: A Phase I Study of ZYC1011
Barbara Klencke; Mark Matijevic; Robert G. Urban; Janet L. Lathey; Mary Lynne Hedley; Michael Berry; Joe Thatcher; Vivian Weinberg; Jennifer Wilson; Teresa Darragh; Naomi Jay; Maria Da Costa; Joel M. Palefsky
Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel1
Nuhad K. Ibrahim; Neil Desai; Sewa Legha; Patrick Soon-Shiong; Richard L. Theriault; Edgardo Rivera; Bita Esmaeli; Sigrid E. Ring; Agop Bedikian; Gabriel N. Hortobagyi; Julie A. Ellerhorst
A Phase I/Pilot Study of Sequential Doxorubicin/Vinorelbine: Effects on p53 and Microtubule-associated Protein 41
Judy Bash-Babula; Deborah Toppmeyer; Marie Labassi; Janice Reidy; Michelle Orlick; Rachelle Senzon; Elizabeth Alli; Thomas Kearney; David August; Weichung Shih; Jin-Ming Yang; William N. Hait
A Phase I Trial of the Farnesyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Lung and Head and Neck Cancer1
Stephen M. Hahn; Eric J. Bernhard; William Regine; Mohammed Mohiuddin; Daniel G. Haller; James P. Stevenson; Debbie Smith; Barnali Pramanik; Joel Tepper; Thomas F. DeLaney; Krystina D. Kiel; Briggs Morrison; Paul Deutsch; Ruth J. Muschel; W. Gillies McKenna
Evaluation of Paclitaxel in Adjuvant Chemotherapy for Patients with Operable Breast Cancer: Preliminary Data of a Prospective Randomized Trial1
Aman U. Buzdar; S. Eva Singletary; Vicente Valero; Daniel J. Booser; Nuhad K. Ibrahim; Zia Rahman; Richard L. Theriault; Ronald Walters; Edgardo Rivera; Terry L. Smith; Frankie A. Holmes; Emma Hoy; Debra K. Frye; Nikki Manuel; Shu-Wan Kau; Marsha D. McNeese; Eric Strom; Eva Thomas; Kelly Hunt; Fred Ames; Donald Berry; Gabriel N. Hortobagyi
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Detection of Circulating Cytokeratin-positive Cells in the Blood of Breast Cancer Patients Using Immunomagnetic Enrichment and Digital Microscopy
Thomas E. Witzig; Blaise Bossy; Teresa Kimlinger; Patrick C. Roche; James N. Ingle; Clive Grant; John Donohue; Vera J. Suman; Douglas Harrington; Jose Torre-Bueno; Kenneth D. Bauer
HER-2 Amplification and Topoisomerase IIα Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil1
Angelo Di Leo; David Gancberg; Denis Larsimont; Minna Tanner; Tero Jarvinen; Ghizlane Rouas; Stella Dolci; Jean-Yves Leroy; Marianne Paesmans; Jorma Isola; Martine J. Piccart
Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Serum and Cytosol of Tumor Tissue from Patients with Primary Breast Cancer1
Rikke Riisbro; Ib J. Christensen; Timo Piironen; Michael Greenall; Berthe Larsen; Ross W. Stephens; Cheng Han; Gunilla Høyer-Hansen; Kenneth Smith; Nils Brünner; Adrian L. Harris
Development and Validation of a Method for Using Breast Core Needle Biopsies for Gene Expression Microarray Analyses1
Matthew Ellis; Natalie Davis; Andrew Coop; Minetta Liu; Lisa Schumaker; Richard Y. Lee; Rujirutana Srikanchana; Chris G. Russell; Baljit Singh; William R. Miller; Vered Stearns; Marie Pennanen; Theodore Tsangaris; Ann Gallagher; Aiyi Liu; Alan Zwart; Daniel F. Hayes; Marc E. Lippman; Yue Wang; Robert Clarke
Experimental Therapeutics, Preclinical Pharmacology
In Vivo Pharmacokinetic Features, Toxicity Profile, and Chemosensitizing Activity of α-Cyano-β-hydroxy-β- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a Novel Antileukemic Agent Targeting Bruton’s Tyrosine Kinase
Fatih M. Uckun; Yaguo Zheng; Marina Cetkovic-Cvrlje; Alexei Vassilev; Elizabeth Lisowski; Barbara Waurzyniak; Hao Chen; Randy Carpenter; Chun-Lin Chen
Inhibition of Angiogenesis by the Antiepidermal Growth Factor Receptor Antibody ImClone C225 in Androgen-independent Prostate Cancer Growing Orthotopically in Nude Mice1
Takashi Karashima; Paul Sweeney; Joel W. Slaton; Sun J. Kim; Daniel Kedar; Jonathan I. Izawa; Zhen Fan; Curtis Pettaway; Daniel J. Hicklin; Taro Shuin; Colin P. N. Dinney
Bradykinin Antagonist Dimer, CU201, Inhibits the Growth of Human Lung Cancer Cell Lines in Vitro and in Vivo and Produces Synergistic Growth Inhibition in Combination with Other Antitumor Agents1
Daniel C. Chan; Lajos Gera; John M. Stewart; Barbara Helfrich; Tom Limin Zhao; Wan Yong Feng; Kenneth K. Chan; Joseph M. Covey; Paul A. Bunn, Jr.
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.